Hamid Riazi-Esfahani Selected Research

Bevacizumab (Avastin)

10/2022	Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema.
7/2022	Intravitreal bevacizumab to treat retinopathy of prematurity in 865 eyes: a study to determine predictors of primary treatment failure and recurrence.
10/2021	Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity.
1/2021	Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors.
1/2021	Autosomal Recessive Bestrophinopathy: Clinical and Genetic Characteristics of Twenty-Four Cases.
1/2020	Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab.
4/2018	Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial.
1/2018	Comparison of Intravitreal Bevacizumab and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hamid Riazi-Esfahani Research Topics

Disease

9	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2024 - 07/2019
7	Macular Edema 10/2022 - 04/2018
6	Retinal Detachment (Retinal Detachments) 02/2023 - 01/2020
6	Retinopathy of Prematurity (Retrolental Fibroplasia) 07/2022 - 01/2018
5	Macular Degeneration (Age-Related Maculopathy) 02/2024 - 10/2014
5	Retinal Vein Occlusion 02/2024 - 07/2019
4	COVID-19 02/2024 - 05/2021
4	Retinoblastoma (Glioblastoma, Retinal) 04/2023 - 01/2021
4	Cataract (Cataracts) 01/2023 - 04/2018
3	Atrophy 03/2023 - 01/2021
2	Cysts 01/2024 - 03/2020
2	Central Serous Chorioretinopathy 09/2023 - 01/2021
2	Breast Neoplasms (Breast Cancer) 07/2023 - 01/2020
2	Retinitis Pigmentosa (Pigmentary Retinopathy) 01/2023 - 10/2014
2	Endophthalmitis (Ophthalmia) 11/2022 - 01/2021
2	Retinal Perforations 10/2022 - 07/2015
2	Lymphoma (Lymphomas) 04/2022 - 02/2022
2	Melanoma (Melanoma, Malignant) 11/2021 - 01/2020
2	Choroidal Neovascularization 01/2021 - 01/2020
2	Neoplasms (Cancer) 01/2021 - 01/2021
1	Fibrosis (Cirrhosis) 03/2024
1	High Hyperopia 03/2024
1	Hamartoma 12/2023
1	Tuberous Sclerosis (Bourneville's Disease) 12/2023
1	Uveal melanoma 08/2023
1	Chronic Renal Insufficiency 04/2023
1	Acute Kidney Injury (Acute Renal Failure) 04/2023
1	photopsia 03/2023
1	Low Vision (Subnormal Vision) 03/2023
1	Langerhans-Cell Histiocytosis (Histiocytosis, Langerhans Cell) 01/2023
1	Heart Failure 01/2023
1	Inflammation (Inflammations) 01/2023
1	Edema (Dropsy) 10/2022
1	Proliferative Vitreoretinopathy 02/2022
1	Retinitis 01/2022
1	Necrosis 01/2022
1	Uveitis 01/2022
1	Ischemia 10/2021
1	Vision Disorders (Hemeralopia) 09/2021
1	Infections 05/2021
1	Retinal Dystrophies 05/2021
1	Vascular Diseases (Vascular Disease) 02/2021
1	Optic Atrophy 01/2021
1	Vitreous Hemorrhage 01/2021
1	Glaucoma 01/2021
1	Corneal Injuries 01/2021
1	Hyphema 01/2021
1	Disease Progression 01/2021
1	Angle-Closure Glaucoma (Glaucoma, Angle Closure) 01/2021
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2021
1	Sickle Cell Trait 01/2021
1	Ocular Toxoplasmosis 01/2021

Drug/Important Bio-Agent (IBA)

27	Retinaldehyde (Retinal)IBA 03/2024 - 10/2014
8	Bevacizumab (Avastin)FDA Link 10/2022 - 01/2018
4	afliberceptIBA 02/2024 - 01/2020
4	Silicone OilsIBA 02/2022 - 12/2020
3	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2021
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 01/2020
2	Tamoxifen FDA LinkGeneric 07/2023 - 01/2020
2	Melphalan (Alkeran)FDA LinkGeneric 04/2023 - 01/2021
2	Fluorescein (Funduscein)FDA LinkGeneric 04/2023 - 01/2022
2	Carboplatin (JM8)FDA LinkGeneric 04/2023 - 01/2021
1	Biosimilar PharmaceuticalsIBA 02/2024
1	Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA 02/2024
1	Selective Estrogen Receptor Modulators (SERM)IBA 07/2023
1	Coloring Agents (Dyes)IBA 04/2023
1	CreatinineIBA 04/2023
1	Niclosamide FDA Link 03/2023
1	ElementsIBA 01/2023
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2023
1	InterferonsIBA 10/2022
1	Methotrexate (Mexate)FDA LinkGeneric 04/2022
1	Rituximab (Mabthera)FDA Link 04/2022
1	Acyclovir (Aciclovir)FDA LinkGeneric 01/2022
1	Ganciclovir (Cytovene)FDA LinkGeneric 01/2022
1	Ruthenium-106IBA 11/2021
1	RutheniumIBA 11/2021
1	dorzolamide (Trusopt)FDA LinkGeneric 05/2021
1	Carbonic Anhydrase InhibitorsIBA 05/2021
1	Retinal Pigments (Pigments, Visual)IBA 01/2021
1	closantelIBA 01/2021
1	Hemoglobins (Hemoglobin)IBA 01/2021
1	TabletsIBA 01/2021

Therapy/Procedure

8	Vitrectomy 02/2023 - 07/2015
5	Drug Therapy (Chemotherapy) 01/2023 - 01/2021
5	Intravitreal Injections 11/2022 - 07/2019
5	Light Coagulation 02/2022 - 01/2018
4	Injections 11/2022 - 01/2021
3	Brachytherapy 08/2023 - 01/2020
2	Phacoemulsification 02/2023 - 06/2018
2	Therapeutics 01/2023 - 06/2019
2	Radiotherapy 04/2022 - 11/2021
2	Aftercare (After-Treatment) 11/2021 - 04/2018
2	Scleral Buckling 09/2020 - 01/2020
1	Slit Lamp 01/2024
1	Photochemotherapy (Photodynamic Therapy) 09/2023
1	Immunotherapy 04/2022
1	Orthoptics (Orthoptic) 09/2021
1	Immunomodulation 05/2021